Evidence map›Paper›PMID 41924566›Full record

ArticleAdvanced functional materials2025

Noninvasive Assessment of Protease Activity in Osteosarcoma via Click Chemistry-Mediated Enrichment of Extracellular Vesicles.

You-Ren Ji, Junseok Lee, Hyoyong Kim, Hui Kong, Chen Zhao, Yong Ju, Ryan Zhang, Jina Kim, Audrey Qian, Diego Sergio Banuet Gonzalez and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

You-Ren JiCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Junseok LeeCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Hyoyong KimCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Hui KongDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Chen ZhaoDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Yong JuCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Ryan ZhangCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Jina KimDepartments of Urology and Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Audrey QianCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Diego Sergio Banuet GonzalezDepartment of Pediatrics, David Geffen School of Medicine, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell, Research and Children's Discovery and Innovation Institute, UCLA, Los Angeles, CA 90095, USA.
Yusef MathkourDepartment of Pediatrics, David Geffen School of Medicine, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell, Research and Children's Discovery and Innovation Institute, UCLA, Los Angeles, CA 90095, USA.
Kenny VoDepartment of Pediatrics, David Geffen School of Medicine, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell, Research and Children's Discovery and Innovation Institute, UCLA, Los Angeles, CA 90095, USA.
Hadar Keren-GillDepartment of Pediatrics, David Geffen School of Medicine, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell, Research and Children's Discovery and Innovation Institute, UCLA, Los Angeles, CA 90095, USA.
Aaron PhungCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Jia-Wei SheSmart Organic Materials Laboratory, Institute of Chemistry, Academia Sinica, No. 128, Section 2, Academia Road, Nankang, Taipei 11529, Taiwan.
Hsiao-Hua YuSmart Organic Materials Laboratory, Institute of Chemistry, Academia Sinica, No. 128, Section 2, Academia Road, Nankang, Taipei 11529, Taiwan.
Sungyong YouDepartments of Urology and Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Hans David UlmertDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Alice SoragniDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
Sarah DryDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Joseph Garfield CromptonDivision of Surgical Oncology, David Geffen School of Medicine, Los Angeles, CA 90095, USA.
Noah FedermanDepartment of Pediatrics, David Geffen School of Medicine, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell, Research and Children's Discovery and Innovation Institute, UCLA, Los Angeles, CA 90095, USA.
Steven John JonasDepartment of Pediatrics, David Geffen School of Medicine, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell, Research and Children's Discovery and Innovation Institute, UCLA, Los Angeles, CA 90095, USA.
Shaohua LuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Yazhen ZhuCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Hsian-Rong TsengCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

Funding

Non-Invasive Prenatal Diagnostics Based on Circulating TrophoblastsU01EB026421 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PISARSKA, MARGARETA, TSENG, HSIAN-RONG · 2019 to 2023
$4.0M
HCC EV Digital Scoring Assay for assessing treatment response in HCC patientsR01CA253651 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG, ZHU, YAZHEN · 2020 to 2024
$3.3M
Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular CarcinomaR01CA255727 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHU, YAZHEN · 2021 to 2025
$3.2M
Integrated analysis of HCC CTCs for Liver Transplant Candidate SelectionR01CA246304 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2020 to 2024
$2.8M
Click Chemistry-Mediated Surface Protein Assay for Quantifying Subpopulations of Hepatocellular Carcinoma-associated Extracellular VesiclesR01CA277530 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vatche Agopian, HSIAN-RONG TSENG · 2023 to 2026
$2.6M
Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular CarcinomaR44CA288163 · NCI · EXIMIUS DIAGNOSTICS CORP · PI CHUANG, HAN-YU, LIU, SEAN XIAO · 2023 to 2025
$2.0M
Novel circulating biomarker digital scores for assessing treatment response in liver cancerR21CA280444 · NCI · CEDARS-SINAI MEDICAL CENTER · PI YANG, JU DONG, ZHU, YAZHEN · 2023 to 2023
$436k
NCI NIH HHS R01 CA246304NCI NIH HHS R01 CA253651NCI NIH HHS R01 CA255727NCI NIH HHS R01 CA277530NCI NIH HHS R21 CA280444NCI NIH HHS R44 CA288163NIBIB NIH HHS U01 EB026421
6 · The paper itself

Abstract

Osteosarcoma (OS), the most common bone cancer in children, is characterized by aggressive tumors and subclinical metastasis. Metastasis significantly impacts OS patient survival rate, highlighting the need for frequent assessment of disease progression and treatment response. The study introduces OS extracellular vesicles (EV) matrix metalloproteinase (MMP) Activity Assay, noninvasively analyzing six combinations of OS EV surface markers and OS-associated MMPs to generate a unique OS EV MMP profile for each patient. An OS EV MMP Activity Score is established from logistic regression of three top-performing combinations to specifically distinguish metastatic OS from localized OS, achieving an area under the receiver operating characteristic (AUROC) curve of 0.97. The Scores from longitudinal monitoring of six OS patients strongly correlate with disease progression and treatment response, as confirmed by radiographic imaging. The OS EV MMP Activity Assay enables noninvasive and timely monitoring of disease progression and treatment response during the critical disease window of progression to metastatic OS, enhancing clinical management for OS patients.

Indexed as

cancer diagnosisextracellular vesiclesliquid biopsymatrix metalloproteinasesosteosarcoma

Identifiers

PMID41924566
PMCPMC13037923

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.